Cantargia has been approved for listing on the main market of Nasdaq Stockholm
Nasdaq Stockholm’s Listing Committee has approved the admission of Cantargia AB’s (publ) (“Cantargia” or the “Company”) shares for trading on the main market of Nasdaq Stockholm. The approval is subject to customary conditions, including the approval and registration of a prospectus by the Swedish Financial Supervisory Authority.
The shares will be traded in the Small Cap segment under the same ticker (CANTA) and ISIN-code (SE0006371126). No new shares will be issued in connection with the list change. Shareholders in Cantargia are not required to take any actions in connection with the delisting from Nasdaq First North Premier or the listing on Nasdaq Stockholm.
The last day of trading on Nasdaq First North Premier is scheduled for 24 September 2018, and the first day of trading on Nasdaq Stockholm’s main market is scheduled for 25 September 2018.
Cantargia has prepared a prospectus for the admission to trading of the Company’s shares on Nasdaq Stockholm’s main market. The prospectus is intended to be published in good time before the first day of trading on the main market.
“Listing on the main market has been a major goal for Cantargia during 2018. We are pleased to have completed that project and look forward to move to a regulated market”, says Göran Forsberg, CEO at Cantargia.
For further information, please contact
Göran Forsberg, CEO
Telephone: +46 (0)46-275 62 60
E-mail: goran.forsberg@cantargia.com
This is information that Cantargia AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 18.00 CET on 13 September 2018.
About Cantargia
Cantargia AB (publ), reg.no. 556791-6019, is a biotech company that is developing antibody-based treatments for life-threatening diseases. The original discovery by the research team behind Cantargia was the overexpression of a specific target molecule, interleukin 1 receptor accessory protein (IL1RAP) in leukemic stem cells. Subsequent research has also identified IL1RAP in many other forms of cancer. The company’s main project, the CAN04 (nidanilimab) antibody targeted against IL1RAP, is being studied in the CANFOUR clinical phase I/IIa study, where the primary focus is on non-small cell lung cancer and pancreatic cancer. CAN04 (nidanilimab) has two modes of action: it blocks the function of IL1RAP and stimulates the immune system to destroy tumour cells. Cantargia’s second project, currently in the research phase, is aimed at developing an IL1RAP-binding antibody that is optimised for treatment of autoimmune and inflammatory diseases.
Cantargia is listed on Nasdaq Stockholm First North Premier (ticker: CANTA). Sedermera Fondkommission is the company’s Certified Adviser. More information about Cantargia is available at http://www.cantargia.com.